$447 Million is the total value of Iron Triangle Partners LP's 25 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRL | CHARLES RIV LABS INTL INC | $29,439,000 | +29.9% | 130,000 | 0.0% | 6.58% | +15.3% | |
| CTLT | CATALENT INC | $23,985,000 | +16.9% | 280,000 | 0.0% | 5.36% | +3.7% | |
| BSX | BOSTON SCIENTIFIC CORP | $22,926,000 | +8.8% | 600,000 | 0.0% | 5.12% | -3.4% | |
| MOH | MOLINA HEALTHCARE INC | $18,304,000 | +2.8% | 100,000 | 0.0% | 4.09% | -8.7% | |
| RPRX | ROYALTY PHARMA PLC | $4,207,000 | -13.3% | 100,000 | 0.0% | 0.94% | -23.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HORIZON THERAPEUTICS PUB LTD | 12 | Q3 2022 | 9.0% |
| GUARDANT HEALTH INC | 12 | Q3 2022 | 6.1% |
| CHARLES RIV LABS INTL INC | 11 | Q1 2023 | 7.8% |
| SURGERY PARTNERS INC | 11 | Q2 2023 | 6.4% |
| ICON PLC | 10 | Q3 2023 | 11.7% |
| BOSTON SCIENTIFIC CORP | 10 | Q3 2023 | 8.9% |
| NEVRO CORP | 10 | Q1 2022 | 6.7% |
| DEXCOM INC | 10 | Q3 2023 | 7.7% |
| ABBVIE INC | 9 | Q3 2023 | 8.1% |
| ACADIA HEALTHCARE COMPANY IN | 9 | Q3 2023 | 7.9% |
View Iron Triangle Partners LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Iron Triangle Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.